Filing Flows › Health Care › Alkermes (ALKS)
Alkermes (ALKS) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 3, 2026 · Alkermes (ALKS) Q3 2026 earnings results →
Q3 2026 Revenue up 22% year over year to $480M · 3¢ of every $1 of revenue kept as net profit · operating margin 7.5%
Alkermes made $480M in Q3 2026 (+22% Y/Y): Product $417M, Royalty $63.2M. Operating margin 7.5%, net earnings $16.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 3, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $480.1M in Q3 2026, up 22% year over year and down 3% from the previous quarter. Vivitrol was the largest line at 27% of revenue. Vivitrol added $6.4M year over year (up 5%), 7% of the total change. Royalty declined 7%.
Operating profit was $36.0M, a 7.5% margin (down 15.1 points year over year). Operating profit fell $53.1M even though revenue rose $85.9M versus Q3 2025, so costs grew faster than sales. Total costs grew 46% against revenue growth of 22%. The fastest-growing cost line was Cost of revenue (+83%). Net earnings were $16.3M, down 80% year over year. The effective tax rate was -10.5%.
Operating cash flow was $93.5M (down 8% year over year), 574% of net earnings. Non-cash charges added back $27.2M of depreciation and amortization and $26.7M of share-based compensation. Working capital and other items added $23.3M. Capital expenditures of $3.4M left free cash flow of $90.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 3, 2026 | $480M | +22% | 7.5% | $16.3M | $93.5M |
| Q2 2026 | 10-Q | Jul 28, 2026 | $496M | +27% | 3.7% | $501K | $145M |
| Q1 2026 | 10-Q | May 5, 2026 | $393M | +28% | -12.3% | −$66.5M | −$166M |
| Q4 2025 | 10-K | Feb 25, 2026 | $385M | -11% | 15.1% | $49.3M | $170M |
| Q3 2025 | 10-Q | Oct 28, 2025 | $394M | +4% | 22.6% | $82.8M | $102M |
| Q2 2025 | 10-Q | Jul 29, 2025 | $391M | -2% | 23.8% | $87.1M | $150M |
| Q1 2025 | 10-Q | May 1, 2025 | $307M | -12% | 4.5% | $22.5M | $98.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- MCK — 38% of its revenue · Stated in 10-K (sentence) · source
- Mc Kesson Corporation — 31% of its revenue · Stated in 10-K (XBRL) · source
- COR — 18% of its revenue · Stated in 10-K (sentence) · source
- CAH — 15% of its revenue · Stated in 10-K (sentence) · source
About Alkermes
The following discussion contains forward-looking statements. Actual results may differ significantly from those expressed or implied in the forward-looking statements. See “Cautionary Note Concerning Forward-Looking Statements” on page 3 of this Annual Report. Factors that might cause future results to differ materially from those expressed or implied in the forward-looking statements include, but are not limited to, those discussed in “Item 1A—Risk Factors” and elsewhere in this Annual Report. Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, and a pipeline of clinical and preclinical candidates in development for neurological disorders.
In its own words, from its 10-K, filed Feb 25, 2026.
Alkermes against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +22% against the peers' median +10%. Operating margin: 7.5% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ALKS Alkermes | Q3 2026 | $480M | +22% | 7.5% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Alkermes 10-Q on SEC EDGAR · CIK 1520262 · Pharmaceutical Preparations
Guidance and outlook
More on ALKS
- How Alkermes makes money: revenue by segment
- Alkermes next earnings date and what analysts expect
- Alkermes stock forecast, price target and fair value
- Who owns Alkermes stock: holders, funds and Congress trades
- Alkermes guidance and outlook
- Is Alkermes a takeover target? LBO and rumors
- Alkermes recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results